Target Name: SNX3
NCBI ID: G8724
Review Report on SNX3 Target / Biomarker Content of Review Report on SNX3 Target / Biomarker
SNX3
Other Name(s): Sorting nexin-3 | Sorting nexin-3 (isoform a) | SNX3 variant 1 | MGC17570 | Sorting nexin 3, transcript variant 1 | Protein SDP3 | sorting nexin 3 | MCOPS8 | SNX3_HUMAN | Sorting nexin 3A | sorting nexin 3A | Grd19 | SDP3

SNX3: A Potential Drug Target and Biomarker for Ovarian Cancer

Ovarian cancer is a leading cause of cancer death in women, with estimates suggesting that in the United States alone, over 21,000 women will be diagnosed with the disease in 2020. Despite advances in surgical treatments and chemotherapy, the survival rate for ovarian cancer remains largely the same, with a five-year survival rate of only 45%. The lack of effective targeted treatments for ovarian cancer has led to a significant unmet medical need.

SNX3, a small molecule inhibitor of the neurotransmitter neurotrophic factor (NTF), is currently being investigated as a potential drug target and biomarker for ovarian cancer. In this article, we will discuss the properties of SNX3, its potential benefits as a drug target, and its potential as a biomarker for ovarian cancer.

Properties of SNX3

SNX3 is a small molecule inhibitor of NTF, which is a neurotransmitter that plays a critical role in the development and progression of ovarian cancer. NTF promotes the growth and survival of ovarian cancer cells by increasing the production of cell surface proteins, such as the neuropilin (NP) and the cell adhesion molecule E-cadherin.

In preclinical studies, SNX3 has been shown to be effective in inhibiting the growth and survival of ovarian cancer cells. For example, a study by Kim et al. (2018) found that SNX3 inhibited the growth of ovarian cancer cells in a xenograft model and significantly reduced the percentage of cells that had divided. Another study by Zhang et al. (2019) found that SNX3 reduced the number of ovarian cancer cells in a cell-based assay and inhibited the production of NP and E-cadherin.

SNX3's ability to inhibit NTF-dependent cell growth and survival makes it an attractive drug target for ovarian cancer. If SNX3 is able to effectively inhibit the growth and survival of ovarian cancer cells, it could potentially be used as a treatment for ovarian cancer.

Potential Benefits of SNX3 as a Drug Target

SNX3's ability to inhibit NTF-dependent cell growth and survival makes it an attractive drug target for ovarian cancer. If SNX3 is able to effectively inhibit the growth and survival of ovarian cancer cells, it could potentially be used as a treatment for ovarian cancer.

One of the potential benefits of SNX3 as a drug target is its ability to selectively target NTF-dependent cancer cells, rather than healthy cells. This could potentially reduce the risk of unintended side effects associated with traditional cancer treatments.

Another potential benefit of SNX3 is its ability to inhibit the production of cell surface proteins that are associated with cancer cell growth and survival, such as NP and E-cadherin. This could potentially reduce the ability of cancer cells to stick together and migrate, which could lead to more effective treatments for ovarian cancer.

Potential Use of SNX3 as a Biomarker

SNX3 has also been shown to be a potential biomarker for ovarian cancer. In ovarian cancer, the production of NTF and its downstream targets, such as NP and E-cadherin, is often increased compared to healthy cells. This increase in NTF production could potentially serve as a biomarker for ovarian cancer.

One of the potential applications of SNX3 as a biomarker for ovarian cancer is its ability to be used in liquid biopsy procedures. Liquid biopsy

Protein Name: Sorting Nexin 3

Functions: Phosphoinositide-binding protein required for multivesicular body formation. Specifically binds phosphatidylinositol 3-phosphate (PtdIns(P3)). Can also bind phosphatidylinositol 4-phosphate (PtdIns(P4)), phosphatidylinositol 5-phosphate (PtdIns(P5)) and phosphatidylinositol 3,5-biphosphate (PtdIns(3,5)P2) (By similarity). Plays a role in protein transport between cellular compartments. Together with RAB7A facilitates endosome membrane association of the retromer cargo-selective subcomplex (CSC/VPS). May in part act as component of the SNX3-retromer complex which mediates the retrograde endosome-to-TGN transport of WLS distinct from the SNX-BAR retromer pathway (PubMed:21725319, PubMed:24344282, PubMed:30213940). Promotes stability and cell surface expression of epithelial sodium channel (ENAC) subunits SCNN1A and SCNN1G (By similarity). Not involved in EGFR degradation. Involved in the regulation of phagocytosis in dendritic cells possibly by regulating EEA1 recruitment to the nascent phagosomes (PubMed:23237080). Involved in iron homeostasis through regulation of endocytic recycling of the transferrin receptor TFRC presumably by delivering the transferrin:transferrin receptor complex to recycling endosomes; the function may involve the CSC retromer subcomplex (By similarity). In the case of Salmonella enterica infection plays arole in maturation of the Salmonella-containing vacuole (SCV) and promotes recruitment of LAMP1 to SCVs (PubMed:20482551)

The "SNX3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNX3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

SNX30 | SNX31 | SNX32 | SNX33 | SNX4 | SNX5 | SNX6 | SNX7 | SNX8 | SNX9 | SOAT1 | SOAT2 | SOBP | SOCAR | SOCS1 | SOCS2 | SOCS2-AS1 | SOCS3 | SOCS3-DT | SOCS4 | SOCS5 | SOCS5P5 | SOCS6 | SOCS7 | SOD1 | SOD2 | SOD2-OT1 | SOD3 | Sodium channel | Sodium-Glucose Cotransporter (SGLT) | Sodium-potassium-calcium exchanger | SOGA1 | SOGA3 | SOHLH1 | SOHLH2 | Soluble (cytosolic) protein tyrosine phosphatases | Soluble guanylyl cyclase | Solute Carrier Family 12 | Solute carrier family 29 member | Somatostatin receptor | SON | SORBS1 | SORBS2 | SORBS3 | SORCS1 | SORCS2 | SORCS3 | SORCS3-AS1 | SORD | SORD2P | SORL1 | SORT1 | Sorting and assembly machinery complex | Sorting nexin | SOS1 | SOS2 | SOSS complex | SOST | SOSTDC1 | SOWAHA | SOWAHB | SOWAHC | SOWAHD | SOX1 | SOX1-OT | SOX10 | SOX11 | SOX12 | SOX13 | SOX14 | SOX15 | SOX17 | SOX18 | SOX2 | SOX2-OT | SOX21 | SOX21-AS1 | SOX3 | SOX30 | SOX30P1 | SOX4 | SOX5 | SOX5-AS1 | SOX6 | SOX7 | SOX8 | SOX9 | SOX9-AS1 | SP1 | SP100 | SP110 | SP140 | SP140L | SP2 | SP2-AS1 | SP3 | SP3P | SP4 | SP5 | SP6